EUPANTOL

Eupantol Adverse Events Reported to the FDA Over Time

How are Eupantol adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Eupantol, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Eupantol is flagged as the suspect drug causing the adverse event.

Most Common Eupantol Adverse Events Reported to the FDA

What are the most common Eupantol adverse events reported to the FDA?

Pyrexia	33 (2.71%)
Cytolytic Hepatitis	31 (2.55%)
Renal Failure Acute	25 (2.05%)
Condition Aggravated	21 (1.73%)
Anaemia	18 (1.48%)
Gamma-glutamyltransferase Increased	16 (1.31%)
Agranulocytosis	15 (1.23%)
Thrombocytopenia	15 (1.23%)
Aspartate Aminotransferase Increase...	14 (1.15%)
Hepatitis	14 (1.15%)
Toxic Skin Eruption	14 (1.15%)
	Show More
Alanine Aminotransferase Increased	13 (1.07%)
Asthenia	13 (1.07%)
Blood Alkaline Phosphatase Increase...	13 (1.07%)
Headache	13 (1.07%)
Pruritus	13 (1.07%)
Vomiting	13 (1.07%)
General Physical Health Deteriorati...	12 (.99%)
Malaise	12 (.99%)
Haemoglobin Decreased	11 (.9%)
Haemorrhage	11 (.9%)
Neutropenia	11 (.9%)
Purpura	11 (.9%)
Blood Creatinine Increased	10 (.82%)
Cholestasis	10 (.82%)
Hyponatraemia	10 (.82%)
Chest Pain	9 (.74%)
Dermatitis Bullous	9 (.74%)
Erythema Nodosum	9 (.74%)
Mouth Ulceration	9 (.74%)
Tachycardia	9 (.74%)
Bone Marrow Failure	8 (.66%)
Cardiac Failure	8 (.66%)
Gastrointestinal Haemorrhage	8 (.66%)
Renal Failure	8 (.66%)
Arthralgia	7 (.58%)
Blood Lactate Dehydrogenase Increas...	7 (.58%)
Eczema	7 (.58%)
Hepatitis Cholestatic	7 (.58%)
Inflammation	7 (.58%)
Multi-organ Failure	7 (.58%)
Skin Fissures	7 (.58%)
Toxic Epidermal Necrolysis	7 (.58%)
Face Oedema	6 (.49%)
Fall	6 (.49%)
Femur Fracture	6 (.49%)
Gastric Ulcer	6 (.49%)
Hepatic Failure	6 (.49%)
Inappropriate Antidiuretic Hormone ...	6 (.49%)
Pancreatitis Acute	6 (.49%)
Rhabdomyolysis	6 (.49%)
Shock Haemorrhagic	6 (.49%)
Systemic Lupus Erythematosus	6 (.49%)
Blood Bilirubin Increased	5 (.41%)
Diarrhoea	5 (.41%)
Eosinophil Count Increased	5 (.41%)
Eosinophilia	5 (.41%)
Epistaxis	5 (.41%)
Haematemesis	5 (.41%)
Hyperhidrosis	5 (.41%)
Hyperproteinaemia	5 (.41%)
International Normalised Ratio Incr...	5 (.41%)
Lactic Acidosis	5 (.41%)
Liver Disorder	5 (.41%)
Lung Disorder	5 (.41%)
Ocular Icterus	5 (.41%)
Pain In Extremity	5 (.41%)
Skin Lesion	5 (.41%)
Stevens-johnson Syndrome	5 (.41%)
Uveitis	5 (.41%)
Antinuclear Antibody Positive	4 (.33%)
Aortic Valve Incompetence	4 (.33%)
Atrial Fibrillation	4 (.33%)
Blood Immunoglobulin E Increased	4 (.33%)
C-reactive Protein Increased	4 (.33%)
Choroiditis	4 (.33%)
Chromaturia	4 (.33%)
Congestive Cardiomyopathy	4 (.33%)
Dermatitis Exfoliative	4 (.33%)
Drug Rash With Eosinophilia And Sys...	4 (.33%)
Eczema Infected	4 (.33%)
Escherichia Urinary Tract Infection	4 (.33%)
Faeces Discoloured	4 (.33%)
Gastrointestinal Disorder	4 (.33%)
Gastrointestinal Ulcer	4 (.33%)
Granuloma	4 (.33%)
Intermediate Uveitis	4 (.33%)
Iridocyclitis	4 (.33%)
Metabolic Disorder	4 (.33%)
Mitral Valve Incompetence	4 (.33%)
Nausea	4 (.33%)
Normochromic Normocytic Anaemia	4 (.33%)
Oesophageal Rupture	4 (.33%)
Pancytopenia	4 (.33%)
Pleural Effusion	4 (.33%)
Pneumomediastinum	4 (.33%)
Post Procedural Complication	4 (.33%)
Rash Macular	4 (.33%)
Rash Maculo-papular	4 (.33%)
Rash Papular	4 (.33%)
Rash Pustular	4 (.33%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Eupantol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Eupantol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Eupantol

What are the most common Eupantol adverse events reported to the FDA?

Epidermal And Dermal Conditions	114 (9.37%)
Hepatic And Hepatobiliary	88 (7.23%)
Hepatobiliary	55 (4.52%)
Renal Disorders	46 (3.78%)
Hematology Investigations	45 (3.7%)
Anemias Nonhemolytic And Marrow Dep...	41 (3.37%)
Body Temperature Conditions	36 (2.96%)
White Blood Cell	33 (2.71%)
Infections - Pathogen Unspecified	32 (2.63%)
Gastrointestinal Signs	27 (2.22%)
Platelet	24 (1.97%)
	Show More
Enzyme	21 (1.73%)
Ocular Infections, Irritations And ...	20 (1.64%)
Gastrointestinal Hemorrhages	18 (1.48%)
Gastrointestinal Ulceration And Per...	18 (1.48%)
Respiratory	18 (1.48%)
Renal And Urinary Tract Investigati...	17 (1.4%)
Immunology And Allergy	15 (1.23%)
Cardiac Arrhythmias	14 (1.15%)
Bacterial Infectious	13 (1.07%)
Electrolyte And Fluid Balance Condi...	13 (1.07%)
Headaches	13 (1.07%)
Urinary Tract Signs	12 (.99%)
Oral Soft Tissue Conditions	11 (.9%)
Protein And Chemistry Analyses	11 (.9%)
Skin Vascular Abnormalities	11 (.9%)
Vascular Hemorrhagic	11 (.9%)
Cardiac Valve	10 (.82%)
Decreased And Nonspecific Blood Pre...	10 (.82%)
Joint	10 (.82%)
Lower Respiratory Tract Disorders	10 (.82%)
Administration Site Reactions	9 (.74%)
Exocrine Pancreas Conditions	9 (.74%)
Heart Failures	9 (.74%)
Injuries	9 (.74%)
Skin And Subcutaneous Tissue	9 (.74%)
Connective Tissue Disorders	8 (.66%)
Gastrointestinal Motility And Defec...	7 (.58%)
Musculoskeletal And Connective Tiss...	7 (.58%)
Neurological	7 (.58%)
Protein And Amino Acid Metabolism	7 (.58%)
Therapeutic And Nontherapeutic Effe...	7 (.58%)
Acid-base	6 (.49%)
Bone And Joint Injuries	6 (.49%)
Eye	6 (.49%)
Hypothalamus And Pituitary Gland	6 (.49%)
Muscle	6 (.49%)
Spleen, Lymphatic And Reticulendoth...	6 (.49%)
Allergic Conditions	5 (.41%)
Gastrointestinal Inflammatory Condi...	5 (.41%)
Procedural And Device Related Injur...	5 (.41%)
Skin Appendage Conditions	5 (.41%)
Upper Respiratory Tract Disorders	5 (.41%)
Chemical Injury And Poisoning	4 (.33%)
Coagulopathies And Bleeding Diathes...	4 (.33%)
Endocrine Neoplasms Malignant And U...	4 (.33%)
Gastrointestinal Conditions	4 (.33%)
Inner Ear And Viiith Cranial Nerve	4 (.33%)
Medication Errors	4 (.33%)
Metabolism	4 (.33%)
Musculoskeletal And Connective Tiss...	4 (.33%)
Myocardial	4 (.33%)
Pleural	4 (.33%)
Seizures	4 (.33%)
Thoracic Disorders	4 (.33%)
Vision	4 (.33%)
Angiedema And Urticaria	3 (.25%)
Appetite And General Nutritional	3 (.25%)
Cardiac And Vascular Investigations	3 (.25%)
Deliria	3 (.25%)
Embolism And Thrombosis	3 (.25%)
Fungal Infectious	3 (.25%)
Hematological And Lymphoid Tissue T...	3 (.25%)
Microbiology And Serology	3 (.25%)
Miscellaneous And Site Unspecified ...	3 (.25%)
Musculoskeletal And Soft Tissue Inv...	3 (.25%)
Physical Examination Topics	3 (.25%)
Suicidal And Self-injurious Behavio...	3 (.25%)
Vascular	3 (.25%)
Anterior Eye Structural Change, Dep...	2 (.16%)
Depressed Mood Disorders	2 (.16%)
Diverticular	2 (.16%)
Gastrointestinal Neoplasms Malignan...	2 (.16%)
Gastrointestinal Vascular Condition...	2 (.16%)
Hematopoietic Neoplasms	2 (.16%)
Mycoplasmal Infectious	2 (.16%)
Neurological Disorders Congenital	2 (.16%)
Neuromuscular	2 (.16%)
Peripheral Neuropathies	2 (.16%)
Thyroid Gland	2 (.16%)
Viral Infectious	2 (.16%)
Bladder And Bladder Neck Disorders	1 (.08%)
Bone Disorders	1 (.08%)
Bronchial Disorders	1 (.08%)
Cornification And Dystrophic Skin	1 (.08%)
Fatal Outcomes	1 (.08%)
Gastrointestinal Stenosis And Obstr...	1 (.08%)
Gastrointestinal Tract Disorders Co...	1 (.08%)
Lipid Analyses	1 (.08%)
Lipid Metabolism	1 (.08%)
Metabolic, Nutritional And Blood Ga...	1 (.08%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Eupantol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Eupantol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.